Archives

Up and Coming

Up and Coming from AstraZeneca and EUSA Pharma

May 20, 2019

This feature highlights changes in clinical research organizations’ and sponsors’ personnel.

AstraZeneca
Sunil Verma
has been named VP and head of breast cancer strategy and global clinical leader in oncology R&D at AstraZeneca. Verma led the Department of Oncology at the University of Calgary’s Cumming School of Medicine and served as the medical director of Alberta Health Services’ Tom Baker Cancer Centre.

Novigenix
Swiss cancer diagnostic company Novigenix has named Jan Groen as its new CEO. Groen was previously the president and CEO of MDxHealth SA and the co-founder of ViroClinics, as well as the founder and CEO of DxOrange.

Novartis
Christian Macher, formerly general manager of Novartis Oncology Canada, has been named president of Novartis Canada. Macher will take on overall leadership of all company activities in Canada and will work in collaboration with senior leadership of the Novartis Pharmaceuticals business unit and Sandoz.

resTORbio, Inc.
resTORbio, Inc., has appointed Lloyd Klickstein as its chief scientific officer. Prior to joining the company, Klickstein was the global head of translational medicine for the New Indication Discovery Unit and the Exploratory Disease Area at Novartis Institutes for Biomedical Research.

EUSA Pharma
EUSA Pharma has named Carsten Thiel president of its Europe operations. Thiel was formerly CEO of Abeona Therapeutics. The company also appointed Darrel Cohen head of clinical development. Cohen was previously VP and clinical development leader in Pfizer’s global oncology organization.

Factory-CRO Group
Sapna Hornyak is the new president and CEO of Factory-CRO Group. Hornyak previously led the device and diagnostics practice at Chiltern International Limited.